Peptide Conjugates for Tumor-Specific Chemotherapy
J ournal of Medicinal Chemistry, 2001, Vol. 44, No. 9 1347
(8) Kratz, F.; Beyer, U.; Collery, P.; Lechenault, F.; Cazabat, A.;
Schumacher, P.; Falken, U.; Unger, C. Preparation, character-
ization and in vitro efficacy of albumin conjugates of doxorubicin.
Biol. Pharm. Bull. 1998, 21, 56-61.
(9) Kratz, F.; Muller-Driver, R.; Hofmann, I.; Drevs, J .; Unger, C.
A novel macromolecular prodrug concept exploiting endogenous
serum albumin as a drug carrier for cancer chemotherapy. J .
Med. Chem. 2000, 43, 1253-1256.
(10) Kratz, F.; Beyer, U.; Roth, T.; Tarasova, N.; Collery, P.; Lech-
enault, F.; Cazabat, A.; Schumacher, P.; Unger, C.; Falken, U.
Transferrin conjugates of doxorubicin: synthesis, characteriza-
tion, cellular uptake, and in vitro efficacy. J . Pharm. Sci. 1998,
87, 338-346.
(30) Doods, H. N.; Wienen, W.; Entzeroth, M.; Rudolf, K.; Eberlein,
W.; Engel, W.; Wieland, H. A. Pharmacological characterization
of the selective nonpeptide neuropeptide Y Y1 receptor antago-
nist BIBP 3226. J . Pharmacol. Exp. Ther. 1995, 275, 136-142.
(31) Fabry, M.; Cabrele, C.; Ho¨cker, H.; Beck-Sickinger, A. G.
Differently labeled peptide ligands for rapid investigation of
receptor expression on a new human glioblastoma cell line.
Peptides 2000, 21, 1885-1893.
(32) Takakura, Y.; Hashida, M. Macromolecular drug carrier systems
in cancer chemotherapy: macromolecular prodrugs. Crit. Rev.
Oncol. Hematol. 1995, 18, 207-231.
(33) Sezaki, H.; Hashida, M. Macromolecule-drug conjugates in
targeted cancer chemotherapy. Crit. Rev. Ther. Drug Carrier
Syst. 1984, 1, 1-38.
(11) Rodrigues, P. C.; Beyer, U.; Schumacher, P.; Roth, T.; Fiebig,
H. H.; Unger, C.; Messori, L.; Orioli, P.; Paper, D. H.; Mulhaupt,
R.; Kratz, F. Acid-sensitive poly(ethylene glycol) conjugates of
doxorubicin: preparation, in vitro efficacy and intracellular
distribution. Bioorg. Med. Chem. 1999, 7, 2517-2524.
(12) O’Hare, K. B.; Duncan, R.; Strohalm, J .; Ulbrich, K.; Kopeckova,
P. Polymeric drug-carriers containing doxorubicin and melano-
cyte-stimulating hormone: in vitro and in vivo evaluation
against murine melanoma. J . Drug Target. 1993, 1, 217-229.
(13) Rousselle, C.; Clair, P.; Lefauconnier, J . M.; Kaczorek, M.;
Scherrmann, J . M.; Temsamani, J . New advances in the
transport of doxorubicin through the blood-brain barrier by a
peptide vector-mediated strategy. Mol. Pharmacol. 2000, 57,
679-686.
(14) Derossi, D.; Chassaing, G.; Prochiantz, A. Trojan peptides: the
penetratin system for intracellular delivery. Trends Cell. Biol.
1998, 8, 84-87.
(15) Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by
targeted drug delivery to tumor vasculature in a mouse model.
Science 1998, 279, 377-380.
(16) Tatemoto, K. Neuropeptide Y: complete amino acid sequence
of the brain peptide. Proc. Natl. Acad. Sci. U.S.A. 1982, 79,
5485-5489.
(17) Michel, M. C.; Beck-Sickinger, A.; Cox, H.; Doods, H. N.; Herzog,
H.; Larhammar, D.; Quirion, R.; Schwartz, T.; Westfall, T. XVI.
International Union of Pharmacology recommendations for the
nomenclature of neuropeptide Y, peptide YY, and pancreatic
polypeptide receptors. Pharmacol. Rev. 1998, 50, 143-150.
(18) Mukherjee, S.; Ghosh, R. N.; Maxfield, F. R. Endocytosis. Physiol.
Rev. 1997, 77, 759-803.
(19) Fabry, M.; Langer, M.; Rothen-Rutishauser, B.; Wunderli-
Allenspach, H.; Ho¨cker, H.; Beck-Sickinger, A. G. Monitoring of
the internalization of neuropeptide Y on neuroblastoma cell line
SK-N-MC. Eur. J . Biochem. 2000, 267, 5631-5637.
(20) Beck-Sickinger, A. G.; J ung, G. Structure-activity relationships
of neuropeptide Y analogues with respect to Y1 and Y2 receptors.
Biopolymers 1995, 37, 123-142.
(34) Seymour, L. W. Passive tumor targeting of soluble macromol-
ecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst.
1992, 9, 135-187.
(35) Maeda, H.; Matsumura, Y. Tumoritropic and lymphotropic
principles of macromolecular drugs. Crit. Rev. Ther. Drug
Carrier Syst. 1989, 6, 193-210.
(36) Kratz, F. Drug targeting in antineoplastic chemotherapy: an-
tigens and receptors in the tumor cell surface as an attack point
for selective chemotherapy. Pharm. Unserer Zeit 1995, 24, 14-
26.
(37) Barinaga, M. Peptide-guided cancer drugs show promise in mice.
Science 1998, 279, 323-324.
(38) Fischman, A. J .; Babich, J . W.; Strauss, H. W. A ticket to ride:
peptide radiopharmaceuticals. J . Nucl. Med. 1993, 34, 2253-
2263.
(39) McAfee, J . G.; Neumann, R. D. Radiolabeled peptides and other
ligands for receptors overexpressed in tumor cells for imaging
neoplasms. Nucl. Med. Biol. 1996, 23, 673-676.
(40) Reubi, J . C. Neuropeptide receptors in health and disease: the
molecular basis for in vivo imaging. J . Nucl. Med. 1995, 36,
1825-1835.
(41) Froidevaux, S.; Eberle, A. N.; Heppeler, A.; Maecke, H. R.
Receptor Targeting for Tumor Localisation and Therapy with
Radiopeptides. Curr. Med. Chem. 2000, 7, 971-994.
(42) De J ong, M.; Bakker, W. H.; Breeman, W. A.; Bernard, B. F.;
Hofland, L. J .; Visser, T. J .; Srinivasan, A.; Schmidt, M.; Behe,
M.; Macke, H. R.; Krenning, E. P. Pre-clinical comparison of
[DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3]
octreotide as carriers for somatostatin receptor-targeted scin-
tigraphy and radionuclide therapy. Int. J . Cancer 1998, 75, 406-
411.
(43) Zamora, P. O.; Bender, H.; Gulhke, S.; Marek, M. J .; Knapp, F.
F. J r.; Rhodes, B. A.; Biersack, H. J . Pre-clinical experience with
Re-188-RC-160, a radiolabeled somatostatin analogue for use in
peptide-targeted radiotherapy. Anticancer Res. 1997, 17, 1803-
1808.
(44) Derossi, D.; Calvet, S.; Trembleau, A.; Brunissen, A.; Chassaing,
G.; Prochiantz, A. Cell internalization of the third helix of the
Antennapedia homeodomain is receptor-independent. J . Biol.
Chem. 1996, 271, 18188-18193.
(45) Schmidt, M. C.; Rothen-Rutishauser, B.; Rist, B.; Beck-Sickinger,
A.; Wunderli-Allenspach, H.; Rubas, W.; Sadee, W.; Merkle, H.
P. Translocation of human calcitonin in respiratory nasal
epithelium is associated with self-assembly in lipid membrane.
Biochemistry 1998, 37, 16582-16590.
(46) Koivunen, E.; Arap, W.; Rajotte, D.; Lahdenranta, J .; Pasqualini,
R. Identification of receptor ligands with phage display peptide
libraries. J . Nucl. Med. 1999, 40, 883-888.
(47) Rigaudy, P.; Charcosset, J . Y.; Garbay-J aureguiberry, C.; J ac-
quemin-Sablon, A.; Roques, B. P. Attempts to target antitumor
drugs toward opioid receptor-rich mouse tumor cells with
enkephalin-ellipticinium conjugates. Cancer Res. 1989, 49,
1836-1842.
(48) Schally, A. V.; Nagy, A. Cancer chemotherapy based on targeting
of cytotoxic peptide conjugates to their receptors on tumors. Eur.
J . Endocrinol. 1999, 141, 1-14.
(49) Huang, C. M.; Wu, Y. T.; Chen, S. T. Targeting delivery of
paclitaxel into tumor cells via somatostatin receptor endocytosis.
Chem. Biol. 2000, 7, 453-461.
(21) Cabrele, C.; Beck-Sickinger, A. G. Molecular characterization
of the ligand-receptor interaction of the neuropeptide Y family.
J . Pept. Sci. 2000, 6, 97-122.
(22) Kratz, F.; Beyer, U.; Schumacher, P.; Kru¨ger, M.; Zahn, H.; Roth,
T.; Fiebig, H.; Unger, C. Synthesis of new maleimide derivatives
of daunorubicin and biological activity of acid labile transferrin
conjugates. Bioorg. Med. Chem. Lett. 1997, 7, 617-922.
(23) Kru¨ger, M.; Beyer, U.; Schumacher, P.; Unger, C.; Zahn, H.;
Kratz, F. Synthesis and stability of four derivatives of the
anticancer drug doxorubicin for the preparation of chemoimmu-
noconjugates. Chem. Pharm. Bull. 1997, 45, 399-401.
(24) Ingenhoven, N.; Beck-Sickinger, A. G. Fluorescent labeled
analogues of neuropeptide Y for the characterization of cells
expressing NPY receptor subtypes. J . Recept. Signal Transduct.
Res. 1997, 17, 407-418.
(25) J ost, L. M.; Kirkwood, J . M.; Whiteside, T. L. Improved short-
and long-term XTT-based colorimetric cellular cytotoxicity assay
for melanoma and other tumor cells. J . Immunol. Methods 1992,
147, 153-165.
(26) Weber, P. J .; Bader, J . E.; Folkers, G.; Beck-Sickinger, A. G. A
fast and inexpensive method for N-terminal fluorescein-labeling
of peptides. Bioorg. Med. Chem. Lett. 1998, 8, 597-600.
(27) Gordon, E. A.; Kohout, T. A.; Fishman, P. H. Characterization
of functional neuropeptide Y receptors in a human neuroblas-
toma cell line. J . Neurochem. 1990, 55, 506-513.
(28) Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.;
Tierney, S.; Nofziger, T. H.; Currens, M. J .; Seniff, D.; Boyd, M.
R. Evaluation of a soluble tetrazolium/formazan assay for cell
growth and drug sensitivity in culture using human and other
tumor cell lines. Cancer Res. 1988, 48, 4827-4833.
(29) Rudolf, K.; Eberlein, W.; Engel, W.; Wieland, H. A.; Willim, K.
D.; Entzeroth, M.; Wienen, W.; Beck-Sickinger, A. G.; Doods, H.
N. The first highly potent and selective non-peptide neuropeptide
Y Y1 receptor antagonist: BIBP 3226. Eur. J . Pharmacol. 1994,
271, R11-13.
(50) Beck-Sickinger, A. G.; Wieland, H. A.; Wittneben, H.; Willim,
K. D.; Rudolf, K.; J ung, G. Complete L-alanine scan of neuropep-
tide Y reveals ligands binding to Y1 and Y2 receptors with
distinguished conformations. Eur. J . Biochem. 1994, 225, 947-
958.
(51) Means, G. E.; Feeney, R. E. Chemical modifications of proteins:
history and applications. Bioconjugate Chem. 1990, 1, 2-12.
(52) Kratz, F.; Beyer, U.; Schutte, M. T. Drug-polymer conjugates
containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carrier
Syst. 1999, 16, 245-288.
(53) Kaneko, T.; Willner, D.; Monkovic, I.; Knipe, J . O.; Braslawsky,
G. R.; Greenfield, R. S.; Vyas, D. M. New hydrazone derivatives
of adriamycin and their immunoconjugatessa correlation be-
tween acid stability and cytotoxicity. Bioconjugate Chem. 1991,
2, 133-141.